Building Trust in HPV Cancer Prevention — One Conversation at a Time

By Cervivor Communications Director Sara Lyle-Ingersoll

Twenty years ago, the HPV vaccine changed the future of cancer prevention. It now protects against six HPV-related cancers: cervical, anal, vulvar, vaginal, penile, and oropharyngeal (throat) cancers.

Yet scientific progress alone isn’t enough.

While the nation’s Healthy People 2030 initiative has set a goal of 80% of adolescents completing the HPV vaccine series, only about 62% of U.S. teens are currently up to date. Coverage varies widely across the country, with some states reporting fewer than half of adolescents completing the series.   

As National Immunization Awareness Month (NIAM) highlights the lifesaving impact of vaccines, public confidence in immunization is being tested by misinformation, growing distrust, and legal challenges to evidence-based vaccine recommendations.

Portrait of Tamika Felder, a 25-year cervical cancer survivor, founder of Cervivor, and advocate for HPV vaccination and cervical cancer prevention.
Tamika Felder

For 25-year cervical cancer survivor and Cervivor Founder and Chief Visionary Tamika Felder, safeguarding the next generation is personal.

“When I was diagnosed with cervical cancer, there wasn’t a vaccine that could have prevented what happened to me,” she says. “Today’s young people have that opportunity. Protecting that progress means making sure families have access to accurate information, trusted guidance, and the confidence to choose prevention.”

That commitment extends to public policy. Last month, Cervivor joined dozens of leading medical, public health, and patient advocacy organizations in signing an amicus brief in the federal lawsuit American Academy of Pediatrics v. Kennedy, supporting evidence-based vaccine recommendations and the scientific integrity of the nation’s immunization policies.

For National Immunization Awareness Month, we asked HPV cancer survivors, physicians, and public health leaders a simple but urgent question: How do we build trust in the HPV vaccine?

The Evidence Has Never Been Stronger

In countries with high HPV vaccination rates, the impact is unmistakable. A landmark 2026 study from England found that cervical cancer deaths among young women offered the HPV vaccine at ages 12 to 13 had fallen close to zero.

Here in the U.S., researchers continue to document declines in cervical precancers and HPV infections among vaccinated generations. A recent June 2026 clinical trial of adults treated for anal or vulvar precancer reinforced what scientists already know: Early vaccination is one of our strongest tools for preventing HPV-related cancers.  

However, despite decades of compelling evidence, misinformation continues to circulate online. A 2024 study found that HPV vaccine misinformation tends to cluster around four themes:

  • Safety concerns
  • Claims that the vaccine is unnecessary or that “natural” approaches are sufficient
  • Conspiracy theories
  • Distrust of medical authorities

Dr. Michelle Fiscus, MD, FAAP, Chief Medical Officer of the Association of Immunization Managers, has heard them all.

Dr. Michelle Fiscus

“We have been using the HPV vaccine to prevent HPV-related cancers for more than 20 years,” she says. “Vaccines undergo more safety monitoring than any other medical product in the United States, and the HPV vaccine has been used in more than 80 countries. Our safety monitoring systems continue to watch for even rare safety signals, and the HPV vaccine has proven to be extremely safe.”

When people argue that natural immunity is better than vaccination, she offers a perspective that’s difficult to forget.

“The immune response the vaccine creates is natural. The vaccine teaches our immune system to recognize the virus and eliminate it before it can go on to cause cancer,” she says. “What isn’t natural is the surgery, chemotherapy, and radiation needed to treat these cancers after they become established.”

Trust is the Missing Ingredient

If the evidence supporting HPV vaccination is stronger than ever, why do misinformation and misconceptions continue to gain traction?

No one understands that challenge better than physician, healthcare technology leader, and best-selling author Dr. Geeta Nayyar, MD, MBA. In her book, Dead Wrong: Diagnosing and Treating Healthcare’s Misinformation Illness, she examines why misinformation spreads.

Portrait of Dr. Geeta Nayyar, physician, healthcare technology leader, and bestselling author who studies healthcare misinformation and trust.
Dr. Geeta Nayyar

“Facts matter enormously,” she says. “But facts alone do not create trust. When someone is frightened or feels dismissed, presenting more data can sometimes make them feel as though we are arguing with them rather than listening to them.”

According to Dr. Nayyar, people don’t evaluate health information in a vacuum. Their experiences, beliefs, and trust in the messenger shape how they receive new information.

Part of the reason misinformation spreads so easily, she says, is that it rarely looks like misinformation.

“It is often packaged as protection: ‘I’m just asking questions,’ ‘Do your own research,’ or ‘They aren’t telling you the whole story,'” she explains. “That language can be compelling because it offers people a sense of agency while suggesting that trusted institutions are withholding the truth.”

The HPV vaccine presents an additional challenge because it touches on three deeply emotional subjects at once: children, sexuality, and cancer. “We cannot dismiss a parent’s instinct to protect their child,” Dr. Nayyar says. “We have to honor it while helping parents understand that vaccination is itself an act of protection against future cancers.”

From Information to Conversation

For immunization leader Dr. Fiscus, that starts with listening.

“When someone has genuine questions or hesitations about vaccines, I find it’s helpful to ask about the concern and the source of that information,” she says. “If it’s something I’ve heard before, I ask permission to share what I know. If it’s new information, I’ll tell them I understand why it would cause concern and offer to look into it and circle back.”

Dr. Nayyar agrees that people are far more likely to reconsider a belief when they feel respected.

“The goal of every conversation does not have to be immediate agreement. Sometimes the most meaningful outcome is simply leaving the door open. Trust is built through connection, humility, and consistency — not through winning an argument.”

When Survivors Lead, Conversations Change

Statistics tell us what the HPV vaccine can prevent. Survivor stories remind us why prevention matters.

“Survivors and organizations like Cervivor can share compelling stories and facts about the success of the HPV vaccine, not only in the U.S., but around the world,” says Dr. Fiscus. “They can share how much easier it is to prevent HPV-related cancers than to treat them after they have been established.”

Calvin Nokes

For HPV cancer survivor Calvin Nokes, the lesson came the hard way. “For years, whenever HPV was mentioned, it was almost always connected to women and cervical cancer,” he says. “I honestly believed it was something only women had to worry about. No one ever told me men could get HPV.”

Everything changed when he was diagnosed with anal cancer in 2009. 

“That’s why I say everywhere I go, ‘Men get HPV, too. Men get HPV-related cancers, too,'” he says. “HPV doesn’t care whether you’re male or female. Boys grow up to become men, and they should be vaccinated, too. We have the opportunity to protect today’s children before they ever face that risk.”

Cervical cancer survivor Athena Porter knows that building trust starts with understanding your audience. 

A Cervivor Ambassador, rural Iowa resident, and woman of faith, Athena leads Cervivor’s virtual Bible study. When questions arise about the persistent myth that the HPV vaccine somehow encourages promiscuity, she doesn’t argue. Instead, she gently reframes the conversation. 

“A person can be cautious and not engage in sexual relations until they get married,” she says, “but there is no guarantee that their future spouse did the same.”

For Athena, emphasizing that the vaccine is about cancer prevention — not sexual activity — helps families see the issue through a different lens. Since graduating from Cervivor School in 2025, she’s continued bringing that message to her community, including in a recent television interview about the importance of HPV vaccination.

Athena Porter, with her husband and their two daughters, who live in rural Iowa.

Protecting Progress Starts with Us

The HPV vaccine has already changed the future of cancer prevention. Protecting that progress, however, will require more than scientific breakthroughs. It will take trusted conversations, compassionate listening, and people willing to share their stories. 

As Tamika puts it, “Advocacy isn’t about having all the answers. It’s about being willing to listen, share your story, and help someone make an informed decision. If one conversation leads to one family choosing cancer prevention, that’s how real change happens.” 

Dr. Nayyar offers similar advice for anyone who wants to help build trust: “Begin with curiosity rather than correction. Ask, ‘What concerns you most about the vaccine?’ Then listen without interrupting or judging.”

Here’s how you can help protect progress:

  • If you’re a parent or caregiver: Talk with your child’s healthcare provider about the HPV vaccine. It’s routinely recommended for girls and boys at ages 11 to 12 and can begin as early as age 9.
  • If you’re an HPV-related cancer survivor: Your experience has the power to build trust in ways statistics alone cannot. Sharing your story may be the conversation that helps another family choose prevention.
  • If you’re ready to advocate: Register for Cervivor’s upcoming Gynecological Cancer Survivors Retreat and Advocacy Training (September 24 to 27) to strengthen your skills, connect with fellow survivors, and help advance HPV vaccination, early detection, and equitable care.
  • Wherever you are: Share credible information, lead with empathy, and keep the conversation going. Every respectful discussion is an opportunity to protect someone from an HPV-related cancer.

Because that’s how progress is protected — one conversation, one informed decision, and one less cancer diagnosis at a time.

About the Author

SARA LYLE-INGERSOLL is a content and communications expert dedicated to transforming lived experiences into impactful stories. Her award-winning magazine feature about a close friend who died from cervical cancer in their twenties led her to Cervivor, and solidified her commitment to cervical cancer awareness and prevention. Now, as Cervivor’s Communications Director, Sara brings this mission full circle.

Happy 20th Birthday, HPV Vaccine: A Love Letter on International HPV Awareness Day 2026

By Sara Lyle-Ingersoll, Cervivor Communications Director

Happy 20th birthday, HPV vaccine!

Two decades is a big deal. Cervivor marked the same milestone last year, so we know a bit about what 20 years of impact feels like.

We still remember the excitement in 2006 when the first HPV vaccine was approved by the U.S. Food and Drug Administration (FDA). The news made the cover of Time magazine and the front page of The New York Times. But it wasn’t just another medical headline — it was a major scientific breakthrough. The idea that we could prevent cervical cancer before it ever started felt revolutionary. The hope was palpable.

Which makes today, International HPV Awareness Day — part of the International Papillomavirus Society‘s (IPVS) annual campaign to promote HPV prevention, screening, and care — a fitting moment to say happy birthday, thank you, and keep up the good work. Consider this our love letter to you, HPV vaccine. 

Why We Love You

Let’s start with the obvious: You prevent cancer.

Not symptoms. Not severity. Cancer. 

HPV is incredibly common — about 80% of people will be infected at some point in their lives. Most infections clear on their own, but some persist and can lead to cancer. Globally, HPV causes nearly all cervical cancers and contributes to cancers of the anus, oropharynx (throat), vulva, vagina, and penis. Together, HPV-related cancers account for more than 720,000 new cancer cases and roughly 350,000 deaths worldwide each year. 

When you were first approved in 2006, you protected against four HPV types, including types 16 and 18, which cause the majority of cervical cancers. Today’s version protects against nine HPV types: seven responsible for about 90% of cervical cancers, plus two that cause most genital warts. That’s pretty badass. Pardon our language.

Because prevention works best before infection occurs, vaccination is recommended between age 11 and 12, and can be given as early as 9. In this video for HPV Day 2026, IPVS envisions a world free from the cancer-causing virus — made possible in large part by you. 

Your Track Record Speaks for Itself

More than half a billion doses of the HPV vaccine have been given out worldwide, and decades of safety monitoring across multiple countries continue to confirm that you are safe. 

Any side effects are typically mild and temporary, and serious reactions are rare. The Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and numerous independent reviews consistently affirm your safety.

And are you effective? Heck, yes! The data is just as strong. 

Countries with high vaccination coverage — think Australia, Rwanda, Sweden — have documented dramatic declines in HPV infections, genital warts, and high-grade cervical precancers among young people. 

This is no longer about projections or promises. The receipts are in. Here are just a few: 

  • A landmark 2020 study published in The New England Journal of Medicine found that Swedish girls vaccinated before age 17 had an 88% lower risk of cervical cancer compared to unvaccinated peers. 
  • In the U.K., research published in The Lancet in 2021 showed nearly a 90% reduction in cervical cancer among women vaccinated between 12 and 13.
  • In the U.S., a 2025 CDC analysis of 2008–2022 data found that cervical precancers among women 20 to 24 — the first generation routinely vaccinated — declined by roughly 80%.

That’s measurable progress and lives saved. Wow, just wow. 

U.S. rates of moderate to severe cervical precancers (CIN2+ and CIN3+) declined sharply from 2008 to 2022 among women 20 to 24 — the first generation routinely vaccinated against HPV. 

We Know It Hasn’t Always Been Easy

From the beginning, you carried more than a syringe and a schedule. You carried stigma — something anyone affected by a below-the-belt cancer understands all too well.

Because HPV is transmitted through intimate contact, conversations about the vaccine have often been wrapped up in discomfort, misinformation, and politics. Some struggle discussing a sexually transmitted virus with preteens. Others falsely claim you’re a “permission slip” for promiscuity. 

At the recent 2026 Cervical Cancer Summit — while unpacking your complicated history — Chief Medical Officer of the Association of Immunization Managers Michelle Fiscus, MD, FAAP, shared an old cartoon poking fun at the promiscuity myth. It showed a young girl receiving the HPV vaccine and saying, “I am so turned on right now.” The joke landed because the premise was so absurd.

A vaccine does not change a child’s values or lifestyle choices. It reduces their risk of cancer. Full stop.

At the 2026 Summit, Association of Immunization Managers CMO Michelle Fiscus emphasized that “misinformation remains one of our biggest barriers,” calling the promiscuity myth “farcical.”

In Case You Need to Hear This

Progress hasn’t been perfect — but that’s not on you. 

Vaccination rates vary widely by region and community. In the U.S., HPV vaccination coverage among adolescents continues to improve, but it still trails other routine adolescent vaccines like Tdap and meningococcal, according to the CDC. Research shows that a strong provider recommendation is one of the biggest factors in increasing HPV vaccination.

Globally, cervical cancer disproportionately affects women in low- and middle-income countries, where access to both vaccination and screening can be limited. The WHO’s strategy to eliminate the disease as a public health problem calls for 90% of girls to be fully vaccinated against HPV by age 15.

It’s simple math: The more people who receive you, the more lives will be saved from HPV-related cancers — which is why we’re your hype girl today and every day. 

For HPV Day, the IPVS shares a message of unity. 

Keep On Keeping On!

HPV vaccine, you have given us a tool that previous generations couldn’t even dream of. 

Twenty years ago, approving the first HPV vaccine was an act of scientific courage and public health ambition. Today, the challenge is simpler — and harder. We have to use it.

Reflecting on the momentum of the first National HPV Conference last April, Cervivor Founder and Chief Visionary Tamika Felder said, “Knowledge is power, but this is just the start. Preventable cancers like cervical cancer are on the rise because of complacency, stigma, and misinformation. The time to prevent suffering — and save lives from cervical and other HPV-related cancers — is now.”

Your moment is now. 

Happy 20th birthday to a vaccine that prevents cancer.

Here’s to a future when a cervical cancer diagnosis or, worse, a death is ancient history. 

P.S. Congratulations to the St. Jude HPV Cancer Prevention Program on five years of saving lives by increasing HPV vaccination rates! We couldn’t be prouder to call you a partner.

About the Author

SARA LYLE-INGERSOLL is a content and communications expert dedicated to transforming lived experiences into impactful stories. Her award-winning magazine feature about a close friend who passed from cervical cancer in their twenties led her to connect with Cervivor’s founder, Tamika Felder, and solidified her commitment to cervical cancer awareness and prevention. Now, as Cervivor’s Communications Director, Sara brings this mission full circle.